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The coronavirus disease 2019 (COVID-19) which started in Wuhan, China, and affected most 
of the country, is spreading rapidly throughout the world in spite of the concerted efforts from 
the governments and World Health Organization (WHO) to contain it. The virus spreads 1000 
times faster than the other viral strains inside the body and causes various kind of illnesses 
[1]. Korea is also adversely affected by COVID-19 due to its geographical proximity to China. 
Considering the high attack rate and aggressive spread of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), there is a concern that more serious diseases may develop due to 
a mutated type of the virus. Some treatment experiences in Korea suggest that steroids played 
an important role in the treatment of COVID-19. According to reports from China, although 
pneumonia was rare in the pediatric population, the risk of pneumonia increased with age and 
had a high mortality rate among the elderly in their 70s (8.0%) and 80s (14.8%) [2].
Clinical experiences in Korea (unpublished) and the data from Chinese COVID-19 reports 
indicate that
1) Symptoms were mild and pneumonia was rare in the pediatric population. The elderly 
was more likely to suffer from severe rapidly progressing pneumonia. [2]
2) Pneumonia was usually self-limited and resolved within a few weeks in people with 
normal immune status, but may result in varying degrees of pulmonary fibrosis.
3) Usually responded well to steroid treatment (personal communications)
Radiology and pathology examinations of patients with COVID-19 revealed inflammatory 
reactions in the lung that resembled what is observed in hypersensitivity pneumonitis rather 
than in other viral pneumonia [3, 4].
Hypersensitivity pneumonitis (HP) has three variants, namely, 1) acute, 2) subacute, and 
3) chronic. The pathophysiology of HP is determined by genetics, environment, age, and 
immune reactions (both innate and adaptive) [5].
The innate immunity is robust in the pediatric population while the complement system and 
adaptive immunity are not mature yet [6]. In contrast, the innate immunity is not effective 
while the complement system is increased in the elderly population. Adaptive immunity 
develops from childhood to adulthood, but declines with older age. Hence, a healthy adult 
who has been exposed to seasonal coronaviruses many times may suffer pneumonia due to 
immune enhancement, which resolves with mobilization of regulatory T cells [7, 8]
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Acute HP is more common in the elderly. The defective innate immunity and the accelerated 
complement activation induced by SARS-CoV-2, similar to that by SARS CoV, leads to a severe 
rapidly progressing pneumonitis due to the triggering effect of the virus [9, 10]. In contrast, 
a healthy adult with normal adaptive immunity controls the inflammatory reaction better 
through immune regulation and manifests as subacute HP. The innate immunity in the 
pediatric population appears to block the viral invasion at the mucosal level, and results in 
minimal to no symptoms.
We believe that there is an urgent need to establish a better sophisticated treatment strategy for 
COVID-19, because there may be a serious risk owing to the subtle mutations of the virus, which 
can lead to a more aggressive spread and more severe immunologic reaction in the host.
HP has been reported in the literature for the past several decades, but its pathophysiology 
remains poorly understood. The possibility of obtaining the exact pathogenesis is less 
with the current knowledge and technology. Considering our current understanding of the 
pathophysiology and clinical features of HP, the treatment strategy for COVID-19 needs to be 
tailored according to the patient's age and immune status. Traditional HP treatment methods 
such as decreasing the antigen (virus) and controlling the abnormal immune response must 
be part of the strategy. SARS-CoV-2 is more likely to spread in the elderly and lead to severe 
pneumonia. Hence, COVID-19 patients would benefit from the administration of antiviral 
medications (nucleotide inhibitors, Human Immunodeficiency Virus (HIV) nucleoside reverse 
transcriptase inhibitor (NRTI), HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), 
HIV protease inhibitor (PI), dextran sulfate, and combination therapy, etc.) that will limit 
the spread of less virulent virus both within the body and in the population. Prophylactic and 
therapeutic low dose steroid oral tablets/inhalers at the earlier stage of COVID-19 and high dose 
steroid treatment according to the severity of the disease can play important roles in decreasing 
the fatality and pulmonary fibrosis. Additionally, safer treatment options that control the 
complement cascade could be considered in cases of acute HP.
God Bless You and me… See the Sky with humble eyes and simple minds.
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